{"prompt": "['Appendix 3: Contraceptive Guidance and Pregnancy Testing', '(1) Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below).', 'Women in the following categories are not considered WOCBP:', 'Premenarchal', 'Premenopausal female with 1 of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's review of the participant's\", 'medical records, medical examination, or medical history interview.', 'Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an alternative', 'medical cause.', 'A high follicle stimulating hormone (FSH) level in the postmenopausal range may', 'be used to confirm a postmenopausal state in women not using hormonal', 'contraception or hormonal replacement therapy (HRT). However, in the absence', 'of 12 months of amenorrhea, confirmation with two FSH measurements in the', 'postmenopausal range is required.', 'Females on HRT and whose menopausal status is in doubt will be required to use one', 'of the non-hormonal highly effective contraception methods if they wish to continue', 'their HRT during the study. Otherwise, they must discontinue HRT to allow', 'confirmation of postmenopausal status before study enrollment.', '(2) Contraception Requirements', 'Male Participants:', 'Male participants with female partners of childbearing potential are eligible to participate if', 'they agree to one of the following beginning at least 1 menstrual cycle prior to starting study', 'drugs, throughout the entire study period, and for 120 days after the last dose of study drug:', 'Be abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', 'Use a male condom plus partner use of a contraceptive method with a failure rate of <1%', 'per year as described in Table 14 when having penile-vaginal intercourse with a woman', 'of childbearing potential who is not currently pregnant.', '76']['Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of penile', 'penetration.', 'Female Participants:', 'Female participants of childbearing potential are eligible to participate if they agree to use a', 'highly effective method of contraception that has a low user dependency consistently and', 'correctly as described in Table 13 during the entire study period and for 120 days after the', 'last dose of study drug:', 'Table 13', 'Highly Effective Contraception Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen- containing ) hormonal contraception', 'b, c', 'Oral', 'Intravaginal', 'Transdermal', 'Injectable', 'Progestogen-only hormonal contraception', 'b,c', 'Oral', 'Injectable', 'Highly Effective Methods That Have Low User Dependency', 'Failure rate of <1% per year when used consistently and correctly.', 'Progestogen- only contraceptive implant', 'b', 'Intrauterine hormone-releasing system (IUS)', 'b', 'Intrauterine device (IUD)', 'Bilateral tubal occlusion', 'Vasectomized partner', 'A vasectomized partner is a highly effective contraception method provided that the partner is the sole', 'male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional', 'highly effective method of contraception should be used.', 'Sexual abstinence', 'Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study treatment. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the', 'preferred and usual lifestyle of the participant.)', 'a. Typical use failure rates are lower than perfect-use failure rates (i.e. when used consistently and correctly).', 'b. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable hormonal contraceptives are limited to', 'those which inhibit ovulation.', 'c. Must be on a stable dose of the same oral hormonal contraceptive product for at least 4 weeks before dosing with study drug and for the', 'duration of the study.', '77']\n\n###\n\n", "completion": "END"}